Ehab Atallah, MD
Hematology & Oncology · Milwaukee, WINPI 1235206285
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Novartis at 25.7% of the total. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $1506.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$88K
- AbbVie$77K
- Bristol Myers Squibb$37K
- E.r. Squibb & Sons, L.L.C.$26K
- Syndax Pharmaceuticals, Inc.$22K
- Jazz Pharmaceuticals Inc.$20K
- plus $73K from 18 others
Across 209 payments — averaging $62,510 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$11.2M
- Takeda Pharmaceuticals U.S.A., Inc.$1.5M
- Astrazeneca UK Limited$78K
- Pfizer$55K
- Incyte Corporation$52K
- Agios Pharmaceuticals, Inc.$52K
- plus $133K from 7 others
What the payments were for
- Consulting fees$140,00941%
- Speaking & faculty fees$150,15844%
- Travel & lodging$46,49114%
- Food & beverage$6,8262%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 41 | $88,119 |
| AbbVie | 54 | $76,914 |
| Bristol Myers Squibb | 22 | $36,677 |
| E.r. Squibb & Sons, L.L.C. | 16 | $26,057 |
| Syndax Pharmaceuticals, Inc. | 9 | $21,970 |
| Jazz Pharmaceuticals Inc. | 20 | $20,304 |
| Novartis Pharma AG | 5 | $11,577 |
| Pfizer | 4 | $7,888 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $6,686 |
| AstraZeneca | 5 | $6,318 |
| Genentech USA, Inc. | 6 | $6,263 |
| Blueprint Medicines Corporation | 4 | $5,059 |
| Foundation Medicine, Inc. | 4 | $4,712 |
| Verastem, Inc. | 2 | $4,443 |
| Rigel Pharmaceuticals, Inc. | 9 | $4,368 |
| Adaptive Biotechnologies Corporation | 7 | $3,984 |
| Servier Pharmaceuticals LLC | 1 | $3,400 |
| Amgen | 6 | $3,340 |
| Agios Pharmaceuticals, Inc. | 1 | $3,300 |
| Beigene USA, Inc. | 2 | $1,919 |
| Geron Corporation | 3 | $105 |
| TG Therapeutics, Inc. | 1 | $64 |
| Janssen Scientific Affairs, LLC | 1 | $44 |
| Gilead | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SCEMBLIX$34,912
- VYXEOS$19,846
- ONUREG$18,756
- Venclexta$18,680
- Reblozyl$18,644
- TIBSOVO$6,700
- AYVAKIT$4,928
- FOUNDATIONACT$4,712
- FOUNDATIONFOCUS$4,712
- FOUNDATIONONE CDX$4,712
- FOUNDATIONONE HEME$4,712
- FOUNDATIONONE$4,712
- ABL002$4,585
- TASIGNA$4,585
- Copiktra$4,443
- Rezlidhia$4,208
- BOSULIF$4,100
- clonoSEQ$3,984
- KYMRIAH$3,912
- Tavalisse$3,523
How this compares
$343,529 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 55 | $617,922 |
| BrukinsaZanubrutinib | 45 | $517,031 |
| CalquenceAcalabrutinib Maleate | 31 | $494,574 |
| JakafiRuxolitinib Phosphate | 20 | $331,209 |
| BosulifBosutinib | 32 | $257,336 |
| SprycelDasatinib | 27 | $179,508 |
| InqoviDecitabine/Cedazuridine | 11 | $88,699 |
| Posaconazole | 20 | $19,225 |
| Acyclovir | 118 | $2,352 |
| Imatinib Mesylate | 21 | $2,161 |
| Allopurinol | 43 | $336 |
| Gabapentin | 15 | $325 |
| Levofloxacin | 27 | $276 |
| Ondansetron Hcl | 16 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $76,914 | $617,92255 claims |
| Beigene USA, Inc.Brukinsa | $1,919 | $517,03145 claims |
| AstraZenecaCalquence | $6,318 | $494,57431 claims |
| PfizerBosulif | $7,888 | $257,33632 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $26,057 | $179,50827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Milwaukee
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
- Renju Vechurettu RajMilwaukee$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.